The Roundhill GLP-1 & Weight Loss ETF (OZEM) seeks to track companies involved in the development, manufacturing, and commercialization of GLP-1 receptor agonist medications and weight loss treatments. This thematic healthcare ETF targets pharmaceutical companies, biotechnology firms, and medical device manufacturers benefiting from the growing obesity treatment market.
How It Works
OZEM uses an actively managed approach to select companies with significant exposure to GLP-1 drugs like Ozempic and Wegovy, weight management therapies, and related medical technologies. The fund employs fundamental analysis to identify firms across the weight loss value chain, from drug developers to medical device companies. Holdings are weighted based on revenue exposure to obesity treatments and market opportunity, with quarterly rebalancing to capture emerging opportunities in this rapidly evolving sector.
Key Features
- First ETF specifically targeting the $100+ billion GLP-1 and weight loss treatment market opportunity
- Active management allows rapid adaptation to breakthrough drug approvals and regulatory changes in obesity medicine
- Launched in May 2024 to capitalize on explosive growth in weight loss pharmaceuticals and medical devices
Risks
- This ETF can lose significant value if GLP-1 drugs face safety concerns, regulatory setbacks, or competition from alternative treatments
- Concentrated exposure to healthcare sector means vulnerability to drug trial failures, patent expirations, and FDA regulatory decisions
- As a new thematic ETF, it faces high volatility and potential permanent loss if the weight loss trend proves temporary
Who Should Own This
Best suited as a small satellite holding (2-5% of portfolio) for aggressive growth investors with 3-5 year time horizons and high risk tolerance. Appropriate for investors seeking targeted exposure to the obesity treatment revolution. Requires ability to withstand 40-60% drawdowns typical of concentrated biotech investments during clinical trial setbacks or regulatory challenges.